CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Niraparibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03759600
NCT03759600Phase 2Completed
CompareCT.gov

A Phase 2, Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Efficacy of Niraparib in Japanese Patients With Advanced, Relapsed, High-grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received 3 or 4 Previous Chemotherapy Regimens

Takeda·interventional·Posted Nov 30, 2018·Updated Jul 16, 2024

In Brief

A Phase 2 clinical trial evaluating Niraparib for Ovarian Cancer and 2 related conditions. Completed, enrolled 20 participants across 33 sites.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of niraparib in participants with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 3 or 4 previous chemotherapy regimens.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedNov 30, 2018
Enrollment StartDec 26, 2018
Primary CompletionDec 28, 2022
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 7.6 years ago

Interventions

Niraparibdrug

Niraparib capsule